New drug combo aims to tame Tough-to-Treat colon cancer
NCT ID NCT06369259
Summary
This study is testing whether a combination of three drugs—avutometinib, defactinib, and cetuximab—can help control advanced colorectal cancer that has spread, cannot be surgically removed, and has stopped responding to standard anti-EGFR therapy. It will enroll about 33 adults to see if the treatment is safe and can shrink or stop the growth of tumors. The goal is to find a new option for patients who have run out of other effective treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77807, United States
Contact
Contact
Conditions
Explore the condition pages connected to this study.